[go: up one dir, main page]

MX2007004274A - Quinazolinilmetilentiazolinonas como inhibidores de cdk1. - Google Patents

Quinazolinilmetilentiazolinonas como inhibidores de cdk1.

Info

Publication number
MX2007004274A
MX2007004274A MX2007004274A MX2007004274A MX2007004274A MX 2007004274 A MX2007004274 A MX 2007004274A MX 2007004274 A MX2007004274 A MX 2007004274A MX 2007004274 A MX2007004274 A MX 2007004274A MX 2007004274 A MX2007004274 A MX 2007004274A
Authority
MX
Mexico
Prior art keywords
quinazolinylmethylene
thiazolinones
cdk1 inhibitors
cdk1
inhibitors
Prior art date
Application number
MX2007004274A
Other languages
English (en)
Inventor
Jin-Jun Liu
Shaoqing Chen
Li Chen
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2007004274A publication Critical patent/MX2007004274A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invencion describe los derivados de quinazolin-tiazolinona de la formula (1), en donde Rl, R3, R4, X y n tienen los significados como se definen en la presente, los cuales demuestran actividad antiproliferativa de CDK1 y son utiles como agentes anti-cancerosos.
MX2007004274A 2004-10-14 2005-10-05 Quinazolinilmetilentiazolinonas como inhibidores de cdk1. MX2007004274A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US61861204P 2004-10-14 2004-10-14
US68107905P 2005-05-13 2005-05-13
PCT/EP2005/010703 WO2006040050A1 (en) 2004-10-14 2005-10-05 Quinazolinylmethylene thiazolinones as cdk1 inhibitors

Publications (1)

Publication Number Publication Date
MX2007004274A true MX2007004274A (es) 2007-05-16

Family

ID=35810865

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007004274A MX2007004274A (es) 2004-10-14 2005-10-05 Quinazolinilmetilentiazolinonas como inhibidores de cdk1.

Country Status (11)

Country Link
US (1) US7501428B2 (es)
EP (1) EP1802614A1 (es)
JP (1) JP2008516904A (es)
KR (1) KR100890533B1 (es)
CN (1) CN101039939B (es)
AU (1) AU2005293832A1 (es)
BR (1) BRPI0518164A (es)
CA (1) CA2583311A1 (es)
MX (1) MX2007004274A (es)
RU (1) RU2405782C2 (es)
WO (1) WO2006040050A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009501776A (ja) * 2005-07-21 2009-01-22 ベタゲノン・エイビー 遊離脂肪酸に起因した障害におけるチアゾール誘導体およびアナログの使用
TW200745066A (en) 2005-09-16 2007-12-16 Torrent Pharmaceuticals Ltd Novel PTP1B inhibitors
WO2008065409A2 (en) * 2006-12-01 2008-06-05 Betagenon Ab Combination for use in the treatment of cancer, comprising tamoxifen or an aromatase inhibitor
WO2010086613A1 (en) 2009-01-30 2010-08-05 Betagenon Ab Compounds useful as inhibitors as ampk
RU2521390C1 (ru) * 2013-03-14 2014-06-27 Общество с ограниченной ответственностью "Тиацен" Производное роданина и средство для профилактики опухолевых заболеваний
EA026332B1 (ru) 2013-03-14 2017-03-31 Общество с ограниченной ответственностью "Тиацен" Применение производных роданина для профилактики и/или лечения опухолевых заболеваний
TW202237585A (zh) 2020-11-27 2022-10-01 瑞士商瑞森製藥公司 Ｃｄｋ抑制劑
WO2022149057A1 (en) 2021-01-05 2022-07-14 Rhizen Pharmaceuticals Ag Cdk inhibitors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6407124B1 (en) * 1998-06-18 2002-06-18 Bristol-Myers Squibb Company Carbon substituted aminothiazole inhibitors of cyclin dependent kinases
EA011807B1 (ru) * 2002-07-10 2009-06-30 Лаборатуар Сероно Са Азолидинонвинильные производные конденсированного бензола
US20050222225A1 (en) 2002-07-10 2005-10-06 Applied Research Systems Ars Holding Nv Use of compounds for increasing spermatozoa motility
CA2507256A1 (en) * 2002-11-22 2004-06-10 Smithkline Beecham Corporation Thiazolidine compounds in the treatment of anemic conditions
US8106214B2 (en) * 2003-07-28 2012-01-31 Merck Serono Sa 2-imino-4-(thio) oxo-5-polycyclovinylazolines for use as PI3 kinase inhibitors

Also Published As

Publication number Publication date
WO2006040050A1 (en) 2006-04-20
US7501428B2 (en) 2009-03-10
BRPI0518164A (pt) 2008-11-04
KR100890533B1 (ko) 2009-03-27
JP2008516904A (ja) 2008-05-22
KR20070053343A (ko) 2007-05-23
CA2583311A1 (en) 2006-04-20
RU2405782C2 (ru) 2010-12-10
US20060084804A1 (en) 2006-04-20
EP1802614A1 (en) 2007-07-04
RU2007117766A (ru) 2008-11-20
AU2005293832A1 (en) 2006-04-20
CN101039939B (zh) 2010-07-07
CN101039939A (zh) 2007-09-19

Similar Documents

Publication Publication Date Title
TW200616978A (en) Quinazolinone derivatives as parp inhibitors
SG154432A1 (en) Quinazolinedione derivatives as parp inhibitors
TW200610531A (en) Phthalazine derivatives as PARP inhibitors
GEP20094785B (en) Pyrrolopyrazoles, potent kinase inhibitors
TW200700422A (en) Compounds for inhibiting ksp kinesin activity
BRPI0717266A2 (pt) Derivados de oxindol
TNSN07195A1 (en) Potentiators of glutamate receptors
EA200801199A1 (ru) Ингибиторы киназы
TW200700066A (en) Compounds for inhibiting ksp kinesin activity
WO2007120333A3 (en) Tetracyclic kinase inhibitors
EA200801200A1 (ru) ПРОИЗВОДНЫЕ ПИРАЗОЛИЗОХИНОЛИНМОЧЕВИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ p38 КИНАЗЫ
BR0313385A (pt) Derivados de pirimidina-2,4-diona como inibidores de metaloproteinase da matriz
MX2009004314A (es) Diaril, dipiridinil y arilpiridinilderivados y usos de los mismos.
NO20081292L (no) Pentasykliske kinaseinhibitorer
MX2007004274A (es) Quinazolinilmetilentiazolinonas como inhibidores de cdk1.
EP1845780A4 (en) USES OF METHYLPHENIDATE DERIVATIVES
TW200610764A (en) Novel quinoline thiazolinones
MX2007004273A (es) Nuevas azaindol-tiazolinonas como agentes anti-cancerosos.
ATE532514T1 (de) Piperidin- und piperazinderivate
WO2006078887A3 (en) Methylphenidate derivatives and uses of them
WO2006027345A3 (en) Novel 3-thia-10-aza-phenanthrene derivatives
ATE407681T1 (de) Metallkomplexierte phospholderivate und pharmazeutische verwendungen dafür
TNSN08190A1 (en) Pyrazole-isoquinoline urea derivatives as p38 kinase inhibitors

Legal Events

Date Code Title Description
FG Grant or registration